Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideki Furuya

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Nature Communications|March 29, 2022
Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumorsFotis Nikolos, Kazukuni Hayashi, Xen Ping Hoi, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-TTanya Dorff, Yosuke Hirasawa, Jared Acoba, et al.
Journal of Translational Medicine|June 18, 2025
Performance of the Oncuria-Detect bladder cancer test for evaluating patients presenting with haematuria: results from a real-world clinical settingIan Pagano, Zhen Zhang, Michael Luu, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 10, 2016
Role of neutral ceramidase in colon cancerMónica García-Barros, Nicolas Coant, Toshihiko Kawamori, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2026
Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder CancerYair Lotan, Michael Luu, Menghan Liu, et al.
Carcinogenesis|October 3, 2017
Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic modelYoshiko Shimizu, Hideki Furuya, Paulette M Tamashiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2024
Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY)Keiju Aokage, Shohei Koyama, Shogo Kumagai, et al.
Diagnostics (Basel, Switzerland)|January 24, 2020
Disabled Homolog 2 (DAB2) Protein in Tumor Microenvironment Correlates with Aggressive Phenotype in Human Urothelial Carcinoma of the BladderYoshitaka Itami, Makito Miyake, Sayuri Ohnishi, et al.
Cells|March 6, 2019
<i>Mycoplasma genitalium</i> Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy SpecimensMakito Miyake, Kenta Ohnishi, Shunta Hori, et al.
Scientific Reports|July 16, 2022
PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activityHideki Furuya, Yuka Sasaki, Runpu Chen, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Nature Communications|March 29, 2022
Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumorsFotis Nikolos, Kazukuni Hayashi, Xen Ping Hoi, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-TTanya Dorff, Yosuke Hirasawa, Jared Acoba, et al.
Journal of Translational Medicine|June 18, 2025
Performance of the Oncuria-Detect bladder cancer test for evaluating patients presenting with haematuria: results from a real-world clinical settingIan Pagano, Zhen Zhang, Michael Luu, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 10, 2016
Role of neutral ceramidase in colon cancerMónica García-Barros, Nicolas Coant, Toshihiko Kawamori, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2026
Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder CancerYair Lotan, Michael Luu, Menghan Liu, et al.
Carcinogenesis|October 3, 2017
Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic modelYoshiko Shimizu, Hideki Furuya, Paulette M Tamashiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2024
Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY)Keiju Aokage, Shohei Koyama, Shogo Kumagai, et al.
Diagnostics (Basel, Switzerland)|January 24, 2020
Disabled Homolog 2 (DAB2) Protein in Tumor Microenvironment Correlates with Aggressive Phenotype in Human Urothelial Carcinoma of the BladderYoshitaka Itami, Makito Miyake, Sayuri Ohnishi, et al.
Cells|March 6, 2019
<i>Mycoplasma genitalium</i> Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy SpecimensMakito Miyake, Kenta Ohnishi, Shunta Hori, et al.
Scientific Reports|July 16, 2022
PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activityHideki Furuya, Yuka Sasaki, Runpu Chen, et al.
Pageof 8